Reduction of interferences in immunoassays

Abstract

The present invention relates to a method for determining an analyte in a sample, comprising a) contacting said sample with at least a first and a second detector compound; b) determining the amount of complexes comprising at least one detector compound; and, c) determining said analyte in a sample based on the result of step b), wherein said first detector compound comprises a first binding moiety and a first label, and said second detector compound comprises a second binding moiety and a second label, and wherein the first label and the second label are non-identical. The present invention further relates to a kit for detecting an analyte in a sample, comprising at least a first and a second detector compound for said analyte, wherein said first detector compound comprises a first binding moiety and a first label, and said second detector compound comprises a second binding moiety and a second label, and wherein the first label and the second label are non-identical; and to a device for determining an analyte in a sample, comprising at least a first and a second detector compound for said analyte, wherein said first detector compound comprises a first binding moiety and a first label, and said second detector compound comprises a second binding moiety and a second label, and wherein the first label and the second label are non-identical; and means for determining at least one signal obtained from said first label and said second label; and to the use of a composition comprising at least a first and a second detector compound for detecting an analyte, wherein said first detector compound comprises a first binding moiety and a first label, and said second detector compound comprises a second binding moiety and a second label, and wherein the first label and the second label are non-identical.

Description

[0001]The present invention relates to a method for determining an analyte in a sample, comprising a) contacting said sample with at least a first and a second detector compound; b) determining the amount of complexes comprising at least one detector compound; and, c) determining said analyte in a sample based on the result of step b), wherein said first detector compound comprises a first binding moiety and a first label, and said second detector compound comprises a second binding moiety and a second label, and wherein the first label and the second label are non-identical. The present invention further relates to a kit for detecting an analyte in a sample, comprising at least a first and a second detector compound for said analyte, wherein said first detector compound comprises a first binding moiety and a first label, and said second detector compound comprises a second binding moiety and a second label, and wherein the first label and the second label are non-identical; and to ...

AI Technical Summary

Benefits of technology

The patent text describes a method for detecting biological molecules using a combination of components. The method involves providing a sample and adding further compounds to facilitate binding and detection. The detection is done using an in vitro method that may involve steps such as providing a sample, adding further compounds, and assisting with automated equipment. The biological molecule detected can be a polypeptide or a detector compound. The method can be used in an immunological method and may involve using antibodies. The technical effect of this patent is to provide a reliable and accurate method for detecting biological molecules.

Problems solved by technology

In case the concentration of analyte in the sample is high, there is a strong competition, leading to a decreased binding of the specifier to the capture compound, causing signal reduction, which, depending on the test format, leads to a quantitative or qualitative test result.

If there is a signal reduction caused by anti-label interferences, this may cause false-positive results.

Anti-label interferences tend to reduce the signal by binding to the label, causing a reduction in signal yield and, thereby, false-negative results.

In some cases anti-label interferences may also increase the signal in non-competitive assay formats, thereby leading to false-positive results.

However, it may be impossible to sufficiently reduce interference by adding more active label, e.g. because the addition of active label would interfere with the assay.

However, since there is a structural difference between the reactive label and the label-analog, the efficiency of label-analogs to reduce anti-label interferences can be limited.

However, such proceeding may entail a significant reduction of signal yield and thereby cause a decrease or an impairment of the detection limit.